FDA approves Bristol Myers Squibb’s schizophrenia drug, first new type of treatment in decades
The first new treatment for schizophrenia in decades
A breakthrough in how we treat and talk about schizophrenia
The Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.
What are the symptoms of schizophrenia? How does Cobenfy work?
Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient’s everyday life, making it difficult to go to school or work, socialize and complete other daily activities. Most people are diagnosed in their late teens to early 30s.
How does Cobenfy work?
Cobenfy is the first treatment approved from a new class of drugs that do not directly block dopamine to improve symptoms of schizophrenia.
Its unique mechanism of action can reduce the risk of major side effects associated with previous antipsychotic therapies, such as weight gain, excessive fatigue and involuntary, uncontrollable movements, without compromising efficacy.
trial results and upcoming research
According to Bristol Myers Squibb, Cobenfy met the main goal of the three clinical trials, significantly decreasing symptoms of schizophrenia compared with a placebo, and mostly led to mild to moderate side effects, which were mainly gastrointestinal and dissipated over time.
Ongoing late-stage clinical trials are examining Cobenfy’s potential in treating other indications, including Alzheimer’s disease patients with psychosis.
Ratings and pricing
Cobenfy will cost $1,850 for a month’s supply or $22,500 annually, according to Bristol Myers Squibb executives. Additionally, the company intends to launch a program aimed at helping patients afford Cobenfy, executives added
Q: How does Cobenfy work?
A: Cobenfy is a new category of treatment, which does not directly affect dopamine receptors; instead, itactivates certain (so-called muscarinic receptors) that decrease dopamine activity without common side effects. The second component of Xanomeline – trospium – reduces some gastrointestinal sideffects
Q: side effects of Cobenfy?
A: The medicine, in normal doses, it mostly leads mild to moderateside effects such as gastrointestinal discomfort
Q: treatment options for schizophrenia. Will Cobenfy change the landscape the landscape ?
Q: When be Cobenfy released and available nationwide?
Q How can patients pay for Cobenfyy?
